MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Sorrento Therapeutics Anteile 2011-2026 | SRNE
Anteile Jährlich Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 295 M | 230 M | 133 M | 106 M | 69.7 M | 50.4 M | 36.9 M | 26.7 M | 15 M | 11.4 M | 9.92 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 295 M | 9.92 M | 89.4 M |
Anteile Vierteljährlich Sorrento Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 543 M | 523 M | 452 M | 403 M | 337 M | 315 M | 299 M | 290 M | 281 M | 268 M | 251 M | 217 M | 183 M | 155 M | 131 M | 123 M | 122 M | 122 M | 117 M | 101 M | 84.9 M | 80.5 M | 76.9 M | 70.3 M | 50.9 M | 58.6 M | 66.2 M | 46.5 M | 38 M | 37.8 M | 37.3 K | 36.3 M | 36.2 M | 29.6 M | 28.5 M | 25.3 K | 23.1 K | 23 M | 14.1 M | 13.4 M | 12.3 M | 12 M | 12 M | 11.2 M | 261 M | 262 M | 262 M | 262 M | 262 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 543 M | 23.1 K | 151 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
272 M | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
27.9 M | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
65.5 M | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
Genmab A/S
GMAB
|
630 M | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
933 K | $ 0.91 | 2.24 % | $ 849 K | USA |
 |
Grifols, S.A.
GRFS
|
682 M | $ 8.4 | 1.63 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 2.51 | 27.16 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
160 M | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
244 M | $ 94.64 | -0.9 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
44.8 M | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
84.5 M | $ 85.79 | 3.72 % | $ 7.25 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
132 M | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
18.3 M | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
24.8 M | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
86.1 M | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
50.2 M | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
306 M | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Nanobiotix S.A.
NBTX
|
34.7 B | $ 41.6 | 19.64 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |